Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

[18F]-Flortaucipir positron emission tomography (PET) is considered a good biomarker of
Alzheimer's disease. However, it is unknown how flortaucipir is associated with the …

Objective Tau pathology is recognized as a primary contributor to neurodegeneration and
clinical symptoms in Alzheimer's disease (AD). This study aims to localize the early tau …

Alzheimer disease (AD) is characterized by accumulation of amyloid-β (Aβ) plaques and tau
neurofibrillary tangles that can be identified at autopsy or during life with fluid or imaging …

Abstract [18F] Flortaucipir is an FDA-approved tau-PET tracer that is increasingly utilized in
clinical settings for the diagnosis of Alzheimer's disease. Still, a large-scale comparison of …

Objective We compared the accuracy of amyloid and [18F] Flortaucipir (FTP) tau positron
emission tomography (PET) visual reads for distinguishing patients with mild cognitive …

Abstract Background [18 F] flortaucipir (FTP) tau PET quantification is known to be affected
by non-specific binding in off-target regions. Although partial volume correction (PVC) …

Background Individuals on the preclinical Alzheimer's continuum, particularly those with
both amyloid and tau positivity (A+ T+), display a rapid cognitive decline and elevated …

INTRODUCTION Alzheimer's disease (AD) and primary age‐related tauopathy (PART) both
harbor 3R/4R hyperphosphorylated‐tau (p‐tau)‐positive neurofibrillary tangles (NFTs) but …